EU Science Hub

JRC News

The principle of alpha-immunotherapy treatment of HIV (click on image to see complete diagram) The principle of alpha-immunotherapy treatment of HIV (click on image to see complete diagram)
©EC (2007)
Feb 14 2009

Today at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago, Ekaterina Dadachova of the Albert Einstein College of Medicine in New York gave a topical lecture on "Novel approaches to the therapy of infectious diseases", detailing the results of a joint project with scientists at the JRC Institute for Transuranium Elements (ITU) on the use of alpha-immunotherapy as a new option for the treatment of HIV infections.

microorganisms Soil is a medium that thrives with life
Feb 15 2009

The JRC hosts a symposium on soil biodiversity today, 15 February, at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago. The session presented an overview of current understanding in the field and attempt to explain the various pressures "life in our soils" is currently under, with an analysis of recent developments that have enhanced our understanding of this crucial, yet unknown ecosystem. The challenges faced by the research community in its support for the sustainable use of this critical, non-renewable natural resource will also be addressed.

Power lines (credit: Nick Benjaminsz) Power lines
©credit: Nick Benjaminsz
Feb 14 2009

Today, at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago, JRC Director-General Roland Schenkel gave a presentation as part of a symposium entitled "Keeping the Lights on: The revival of Nuclear Energy".

Simultaneous first and second polar bodies removal Simultaneous first and second polar bodies removal
©V. Ivakhenko
Feb 16 2009

Today at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago, the JRC organised a scientific symposium on Pre-implantation genetic diagnosis (PGD), a service provided by in-vitro fertilisation (IVF) clinics to parents who want to avoid passing on genetic diseases to their children.

PGD entails carrying out genetic tests on embryos in a laboratory to identify those that have a healthy version of a given gene. These embryos can then be safely implanted in a mother's womb. Not be confused with the more far-reaching and separate issue of actual genetic engineering with a view to creating 'designer babies', PGD enables fertilisation clinics to select embryos for implantation so that at-risk families can avoid passing on genetic disease to their children and to subsequent generations. Nevertheless, many questions continue to surround the technique.

The JRC-organised symposium on PDF featured Dr Tarek El Toukhy from St Thomas' NHS Foundation Trust, London, Susannah Baruch from Johns Hopkins University, Baltimore and the JRC's own Dolores Ibarreta from the JRC Institute for Prospective Technological Studies (IPTS) in Seville. It was moderated by Karen Sermon from the Vrije Universiteit Brussel, Belgium.

A lively debate with the audience followed the session.

EU legislation requires that the Community establish high quality and safety standards for the use of blood, organs and other substances of human origin. A JRC report in late 2007 showed that guidelines were urgently needed on the counselling of patients that opt to screen their embryos created by in vitro fertilisation (IVF) for serious genetic disorders.

Footbridge flooded in Flanders Adaptation efforts should favour measures targeted at reducing the impacts of floods, such as relocation and vulnerability reduction.
©EU, 2013 - credit: D Vanham
Mar 17 2016

Adaptation measures include the rise of flood protections, reduction of the peak flows through water retention, reduction of vulnerability and relocation to safer areas.

dry land Increased occurence of droughts is one of the predicted effects of climate change
©Scott Liddell
Apr 01 2009

The European Commission presented today a White Paper outlining actions needed to strengthen the Union's resilience in coping with a changing climate. Recent findings indicate that the impacts of climate change will be swifter and more severe than indicated by the Intergovernmental Panel on Climate Change in their 2007 report. Europe will not escape these effects and must therefore prepare to cope with them.

The European Commission adopted the JRC's first Work Programme under Horizon 2020 The European Commission adopted the JRC's first Work Programme under Horizon 2020
©EU
Dec 11 2013

The European Commission has adopted the JRC's first Work Programme for 2014-2015 under Horizon 2020, the new EU strategy to boost research and innovation. The programme is aligned with the European Union's policy priorities, such as overcoming the economic crisis, encouraging the use of renewable energy and tackling climate change.

Human body representation Three JRC-developed adverse outcome pathways have been recently published by the OECD
©Fotolia 100886697
Sep 30 2016
The Organisation for Economic Co-operation and Development (OECD) has recently published the first five adverse outcome pathways (AOP), three of which have been developed by the JRC. The AOPs are novel knowledge management tools in toxicology and are useful for supporting risk assessment to human health. They are also valuable for helping to avoid animal testing through the use of alternative methods.
Single 242-PuCoGa5 crystal Single 242-PuCoGa5 crystal
Mar 19 2008

The JRC Institute for Transuranium Elements (ITU) has been involved in the determination of the phonon dispersion curves of single crystalline PuCoGa5 samples by inelastic X-ray scattering (IXS) at room temperature. This was done at the European Synchrotron in Grenoble (ESRF). The understanding of the superconductor PuCoGa5 physical properties will allow advances in the global understanding of unconventional superconductivity.

DNT3 Conference Third International Conference on Alternatives for Developmental Neurotoxicity Testing (DNT3)
May 06 2011

The JRC is hosting the Third International Conference on Alternatives for Developmental Neurotoxicity Testing (DNT3) on 10-13 May 2011 in Varese, Italy. The event brings together over 100 scientists and representatives from academia, industry and governmental organisations working on children's health, alternatives to animal testing and environmental protection.

Pages